Rep. Lisa C. McClain Sells Off Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Representative Lisa C. McClain (R-Michigan) recently sold shares of Roivant Sciences Ltd. (NASDAQ:ROIV). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Roivant Sciences stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Roivant Sciences Stock Up 1.6%

NASDAQ:ROIV traded up $0.32 during trading hours on Tuesday, reaching $20.62. The company had a trading volume of 2,744,906 shares, compared to its average volume of 6,509,113. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $21.35. The firm has a market cap of $14.34 billion, a price-to-earnings ratio of -36.78 and a beta of 1.23. The business’s 50-day simple moving average is $17.79 and its two-hundred day simple moving average is $13.74.

Analyst Ratings Changes

Several research analysts have weighed in on ROIV shares. HC Wainwright upped their price objective on shares of Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. Weiss Ratings upgraded Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Saturday, October 25th. Wall Street Zen raised shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. Citigroup increased their target price on shares of Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Finally, Bank of America boosted their price target on shares of Roivant Sciences from $12.00 to $16.50 and gave the stock a “neutral” rating in a report on Thursday, September 18th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.56.

Institutional Trading of Roivant Sciences

A number of large investors have recently added to or reduced their stakes in ROIV. Jones Financial Companies Lllp increased its stake in shares of Roivant Sciences by 226.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after purchasing an additional 1,148 shares during the last quarter. Bessemer Group Inc. lifted its holdings in Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the last quarter. CWM LLC boosted its position in Roivant Sciences by 44.6% during the second quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after purchasing an additional 920 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Roivant Sciences by 94.8% in the first quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company’s stock worth $46,000 after purchasing an additional 2,233 shares in the last quarter. Finally, Osaic Holdings Inc. raised its position in shares of Roivant Sciences by 204.2% in the second quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock valued at $65,000 after purchasing an additional 3,882 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insider Activity at Roivant Sciences

In related news, Director Daniel Allen Gold sold 1,300,000 shares of the company’s stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $20.23, for a total value of $26,299,000.00. Following the completion of the transaction, the director directly owned 18,047,727 shares in the company, valued at approximately $365,105,517.21. The trade was a 6.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric Venker sold 683,818 shares of the firm’s stock in a transaction dated Friday, September 19th. The shares were sold at an average price of $14.95, for a total value of $10,223,079.10. Following the sale, the chief executive officer owned 1,969,767 shares in the company, valued at $29,448,016.65. The trade was a 25.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 8,483,561 shares of company stock valued at $143,557,750. Corporate insiders own 10.80% of the company’s stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.